Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience

Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma

(2017) Sith Sathornsumetee et al.   NEURO-ONCOLOGY

Expression of EGFRvIII in Glioblastoma: Prognostic Significance Revisited

(2015) Nicola Montano et al.   NEOPLASIA

Phase 1 trial of dasatinib plus erlotinib in adults with recurrent malignant glioma

(2012) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Radiation necrosis following treatment of high grade glioma—a review of the literature and current understanding

(2011) Alan Siu et al.   ACTA NEUROCHIRURGICA

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme

(2011) O. L. Chinot et al.   ADVANCES IN THERAPY

A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy

(2011) J. J. Raizer et al.   NEURO-ONCOLOGY

Preliminary experience with personalized and targeted therapy for pediatric brain tumors

(2011) Johannes E. Wolff et al.   PEDIATRIC BLOOD & CANCER

The BATTLE Trial: Personalizing Therapy for Lung Cancer

(2011) Edward S. Kim et al.   Cancer Discovery

Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN

(2010) Ana Custodio et al.   Clinical & Translational Oncology

Should biomarkers be used to design personalized medicine for the treatment of glioblastoma?

(2010) Michael Weller et al.   Future Oncology

Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group

(2010) Patrick Y. Wen et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells

(2010) Lucia Ricci-Vitiani et al.   NATURE

Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study

(2010) W. K. A. Yung et al.   NEURO-ONCOLOGY

Genetic alterations and signaling pathways in the evolution of gliomas

(2009) Hiroko Ohgaki et al.   CANCER SCIENCE

EGF receptor inhibitors in the treatment of glioblastoma multiform: Old clinical allies and newly emerging therapeutic concepts

(2009) Macoura Gadji et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

The EGFRvIII variant in glioblastoma multiforme

(2009) Hui K. Gan et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma

(2009) Henry S. Friedman et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

(2009) Martin J. van den Bent et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma

(2009) David A. Reardon et al.   JOURNAL OF NEURO-ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

Biology of angiogenesis and invasion in glioma

(2009) Matthew C. Tate et al.   Neurotherapeutics

FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme

(2009) M. H. Cohen et al.   ONCOLOGIST

Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme

(2008) R. Pallini et al.   CLINICAL CANCER RESEARCH

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

(2008) J. F. de Groot et al.   JOURNAL OF NEURO-ONCOLOGY

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas

(2008) Dieta Brandsma et al.   LANCET ONCOLOGY

Antitumor Activity of Rapamycin in a Phase I Trial for Patients with Recurrent PTEN-Deficient Glioblastoma

(2008) Tim F Cloughesy et al.   PLOS MEDICINE